CDT Equity Names James Bligh CEO as Shareholders Approve Massive Dilution and Reverse Split
CDT is trading near its 52-week low of $1.6 (1.3% below the low) on light trading volume (0.2× avg).
Summary
CDT Equity appointed James Bligh as CEO and announced Dr. Andrew Regan's resignation, while stockholders approved up to 12.1 million shares of dilution and a reverse split of up to 1-for-500.
Key Events · Executive and Board Changes · CDT
-
CEO Transition
James Bligh appointed CEO effective August 31, 2026, with $600,000 base salary and 50% target bonus; Dr. Andrew Regan resigned with $50,000/month severance for six months.
-
Massive Dilution Approved
Stockholders approved issuance of up to 12,131,770 shares upon exercise of pre-funded warrants, plus additional shares for J.J. Astor & Co. convertible note and warrant.
-
Reverse Split Authorized
Stockholders approved reverse stock splits ranging from 1-for-2 to 1-for-100, with aggregate up to 1-for-500, at board discretion.
-
Cash Crisis Context
Company had only $747,000 in cash as of Q2 2026, with a going concern warning and missed debt payments.
Analysis · CDT · Life Sciences
CDT Equity replaced its CEO and secured stockholder approval for up to 12.1 million shares from pre-funded warrants and a reverse split of up to 1-for-500. The leadership change comes with a $600,000 salary for the new CEO and a $300,000 severance package for the outgoing one, while the company burns through its remaining $747,000 in cash. The approved dilution and reverse split are survival tools for a company trading near its 52-week low with a going concern warning.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $1.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $1.60 to $2,739.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.